The Technology Gap in Type 1 Diabetes: Why Access Matters as Much as Innovation
D-Coding the article :Barriers to the Adoption of Diabetes Technologies and the Implementation of Connected Insulin Pens in a Largely Minority Population With Type 1 Diabetes
Published Date:
July 30, 2023
Published By:
Maria A. Yanez Bello and Colleagues
Approved By:
To be
Decoded By:
Asra H. Ahmed MBA, PGCE in Assessment Learning disability, The Diabesties Foundation
5 mins to read
- The T1D Takeaway
- Every diabetes conference showcases the latest technology. Yet for many people with Type 1 diabetes, the biggest challenge is not choosing between a CGM, pump, or smart pen—it is getting access to any of them.
Summary Snap
Shots
Diabetes technology exists, but many people still cannot access it. Barriers included affordability, insurance approval, education, language, and healthcare support. Connected insulin pens may help bridge the gap for people who are not using insulin pumps and can be an option.
Prime Insight
Many people with Type 1 diabetes are not missing out on technology because they do not want it—they face barriers such as cost, insurance problems, lack of education, language differences, and difficulty accessing healthcare.
Better support and more affordable options, such as connected insulin pens, could help more people benefit from diabetes technology and reduce inequalities in diabetes care. Despite these innovations, many people with Type 1 diabetes still do not have access to these tools.
The greatest innovation in diabetes care is not the newest device. It is making sure the device reaches the people who need it most.
Although conducted in Miami, the findings are relevant to minority and underserved communities worldwide, where similar barriers often prevent people from benefiting from diabetes technologies.
Minority and underserved populations consistently show lower rates of technology use and poorer diabetes outcomes. Researchers wanted to understand why these disparities persist and identify practical solutions to improve access.
Researchers examined who was using diabetes technology, the barriers preventing access, the impact of insurance and financial challenges, clinical outcomes, and people’s experiences with connected insulin pens. They found that many obstacles occurred long before individuals even had the opportunity to try diabetes technology. Many people with Type 1 diabetes still face barriers such as cost, insurance restrictions, language differences, limited education, and difficulty accessing healthcare, preventing them from benefiting from diabetes technology.
Connected insulin pens may provide a practical and more accessible option for some people but improving diabetes outcomes will require deliberate efforts to ensure that technology reaches everyone who could benefit from it.
Most importantly, the study reminds us that innovation alone does not create equity. Intentional efforts are needed to ensure advances reach everyone who could benefit.
- A Deeper Dive
- A landmark clinical trial testing a fully automated closed-loop system across multiple age groups, with significant findings on time-in-range improvements and reduced hypoglycemia
- This paper zooms in on the psychological dimension of T1D technology, exploring how CGMs and pumps influence mental health, family relationships, and school life for young people with T1D.
- The Sources Voice
“The question is no longer whether diabetes technology works. We know it works. The question is whether the people who need it most can access it.” Maria A. Yanez Bello and colleagues
This shift in focus—from innovation to implementation—may be one of the most important conversations in diabetes care today
- Curiosities Clarified
The biggest barriers were not the devices themselves. Cost, insurance approval, language differences, limited education, and difficulty navigating healthcare systems prevented many people from accessing technology.
Previous studies have shown that minority and underserved communities are less likely to use diabetes technologies and often have poorer diabetes outcomes. Understanding these barriers is the first step toward reducing health inequities.
A connected insulin pen records insulin doses and sends the information to a smartphone app. It can help users track injections, identify missed doses, and make insulin management easier.
No. Even when devices are covered, barriers such as lack of training, language support, healthcare access, and confidence using technology can still prevent adoption.
Innovation alone is not enough. The benefits of diabetes technology can only be realized when people can access, understand, and successfully use these tools in their daily lives.